G&A

Autonomix Medical, Inc. Reports Full Year 2024 Financial Results and Provides Corporate Update

Retrieved on: 
пятница, мая 31, 2024
Insurance, Nervous system, Patient, AMIX, Fiscal, Patent, Clinical trial, Calendar, Application-specific integrated circuit, Travel, Trial of the century, Disease, Marketing, Collateral damage, Ethanol, Pancreatic cancer, IPO, POC, Advertising, NFR, Research, G&A, Renal artery, Pain, Quality of life, Completeness, Pharmaceutical industry

THE WOODLANDS, TX, May 31, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today reported financial results for the fiscal year 2024 ended March 31, 2024 and provided a corporate update.

Key Points: 
  • THE WOODLANDS, TX, May 31, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today reported financial results for the fiscal year 2024 ended March 31, 2024 and provided a corporate update.
  • Results from the preclinical study demonstrated statistically significant reduction of metastases and statistically significant reduction in tumor mass.
  • “I am incredibly pleased with the progress we have made on the corporate, financial and clinical fronts over the course of our fiscal year 2024.
  • We are grateful for the continued support and remain focused on successfully executing on the milestones laid out ahead of us.

BW LPG Limited - Financial Results for Q1 2024

Retrieved on: 
четверг, мая 30, 2024
Oil, Gas, Alternative Energy, Energy, Maritime, Transport, EIA, USD, Panama Canal, CFO, Calendar, Sale, VLGC, Growth, Hyundai Heavy Industries, Interim, Propane, OPEX, Congestion, G&A, Oslo Stock Exchange, LPG, LNG, TCE, NPAT, YTD, Water, Pharmaceutical industry

- BW LPG successfully listed on the New York Stock Exchange (NYSE) on 29 April 2024.

Key Points: 
  • - BW LPG successfully listed on the New York Stock Exchange (NYSE) on 29 April 2024.
  • BW LPG Limited (“BW LPG”, the “Company”, NYSE ticker code: “BWLP”, OSE ticker code: “BWLPG.OL”) reported a Q1 2024 Net Profit After Tax (NPAT) of USD 150 million, yielding an annualised return on equity of 37% with USD 468.5 million free cash flow generated.
  • BW LPG delivered BW Princess (2008-built, Hyundai Heavy Industries, Korea) in February 2024 to new owners for further trading.
  • More information is available in the press release dated 21 May 2024 “BW LPG Limited – Notice of Scheme meeting regarding redomiciling to Singapore”.

Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update

Retrieved on: 
среда, мая 29, 2024
Montreal Heart Institute, Assay, Pharmacokinetics, SAD, Investment, Urine, Trial of the century, Safety, CZO, MBA, Blood, Litre, Growth, Avenanthramide, Data monitoring committee, Health Canada, G&A, Hand, GMP

EDMONTON, Alberta, May 29, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the first quarter ended March 31, 2024.

Key Points: 
  • The first arm of the single ascending dose (SAD) phase of the study has been completed.
  • 6 groups of 8 subjects per group received doses ranging from 30mg to 960mg per group per day.
  • This is the first-in-human clinical study to assess safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of avenanthramides.
  • Financial Highlights for the First Quarter Ended March 31, 2024
    Total sales of $2,800,000 for the first quarter of 2024 compared to $3,500,000 for the comparative quarter in 2023.

Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

Retrieved on: 
вторник, мая 21, 2024
Partnership, CTA, Patient, EBIDTA, Icelandic, Food, Movement, Clinical trial, FDA, EDT, Marketing, Ustekinumab, Food and Drug Administration, Absorption, Denosumab, Research, G&A, Biosimilar, Adalimumab, Webcast, Teva, Teva Pharmaceuticals, Generic drug

Gross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last year.

Key Points: 
  • Gross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last year.
  • Alvotech raises topline revenue guidance to $400-$500 million and tightens guidance for bottom line range for 2024 to $100-$150 million.
  • Management will conduct a business update conference call and live webcast on Wednesday May 22, 2024, at 8:00 am ET (12:00 pm GMT).
  • Alvotech will conduct a business update conference call and live webcast on Wednesday, May 22, 2024, at 8:00 am EDT (12:00 pm GMT).

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

Retrieved on: 
понедельник, мая 20, 2024
Partnership, Serum sickness, Exercise, Sale, MD, Research, Research and development, SAB, Immunotherapy, G&A

MIAMI, May 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today reported financial results for the first quarter ended March 31, 2024, and provided a company update.

Key Points: 
  • MIAMI, May 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today reported financial results for the first quarter ended March 31, 2024, and provided a company update.
  • SAB continues to execute its corporate strategy through building partnerships and expertise that advance its program focus on T1D.
  • This includes a recent May 1, 2024 vote by the SAB Board of Directors to appoint renowned T1D expert Dr. Jay Skyler, MD to the SAB Board of Directors.
  • Additionally, the SAB executive team recently transitioned its corporate headquarters to Miami, FL, while retaining its Research and Development Campus in South Dakota.

Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
понедельник, мая 20, 2024
Insurance, Patient, Hepatectomy, Liver disease, PMDA, Marketing, McGill University Health Centre, Colorectal cancer, KPC, Clinical trial, Neoplasm, Government, D&O, Head, Safety, Alpha Sigma Tau, Congress, Pancreatic cancer, Brain, Carcinoma, Rambam Health Care Campus, Lung cancer, Alpha, G&A, Liver cancer

JERUSALEM, May 20, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported first quarter 2024 financial results and provided a corporate update.

Key Points: 
  • Alpha Tau anticipates remaining adequately capitalized to support all of these programs over the coming years," he concluded.
  • In May, preclinical data demonstrating an abscopal immune effect in pancreatic murine tumor models was presented at ESTRO 2024 Congress in Glasgow.
  • Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated with Alpha DaRT alone.
  • Targeting completion of patient recruitment in the ReSTART U.S. multi-center pivotal trial in recurrent cutaneous squamous cell carcinoma in H2 2024.

Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
четверг, мая 16, 2024
ARK, Insurance, Patient, LP, Risk, Urinary tract infection, Neutropenia, COVID19, Sale, Ritonavir, CDK, Cancer, Acquisition, OrbiMed, Omicron, COVID, COVID 19, Research, G&A, Infection, Delta, SARS-CoV-2, Pharmaceutical industry

NEWTOWN, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer, today announced financial results for the first quarter of 2024, and provided a business update.

Key Points: 
  • Excellent pipeline progress, led by candidates for COVID 19, influenza, and oncology programs
    NEWTOWN, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer, today announced financial results for the first quarter of 2024, and provided a business update.
  • “2024 has already been a transformative year for Traws Pharma to advance our portfolio of novel treatments for serious respiratory infections and oncology programs.
  • Furthermore, we completed the last dose escalation cohort for our CDK4+ inhibitor, narazaciclib,” stated Werner Cautreels, Ph.D., Chief Executive Officer of Traws Pharma.
  • The Company believes that its cash and cash equivalents will be sufficient to fund ongoing clinical trials and business operations into the fourth quarter of 2024.

Zealand Pharma Announces Financial Results for the First Quarter of 2024

Retrieved on: 
четверг, мая 16, 2024
DREAM, Partnership, Credit, Patient, European Investment Bank, F2, CGM, Short bowel syndrome, Complement component 3, NDA, US FDA, Obesity, EASL, Clinical trial, Congress, Overweight, FDA, S&M, DKK, Boehringer Ingelheim, Danske Bank, PDUFA, Cirrhosis, EUR, SBS, F1, Weight loss, Part, G&A, EIB, BofA Securities, Pharmaceutical industry

Cash position includes cash, cash equivalents and marketable securities, as well as Tranche A of EIB loan disbursed in Q1 2024.

Key Points: 
  • Cash position includes cash, cash equivalents and marketable securities, as well as Tranche A of EIB loan disbursed in Q1 2024.
  • Survodutide, a glucagon/GLP-1 receptor dual agonist: Boehringer Ingelheim announced positive results from Phase 2 trial in MASH.
  • These results will be presented at the European Association for the Study of the Liver (EASL) congress in Milan, Italy on June 7, 2024.
  • Zealand expects to initiate the first-in-human clinical trial of ZP9830 in the second half of 2024.

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
среда, мая 15, 2024
Patient, JAMS, Prejudice, Ovarian cancer, Patent, Element, University, FDA, Bank statement, Sale, Autoimmune disease, Pancreatic cancer, Court, Research, Notifiable disease, Inflammation, G&A, District court, Clinical trial, Skin, Court of Chancery, Complaint, Pharmaceutical industry

MIRAMAR, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2024.

Key Points: 
  • MIRAMAR, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2024.
  • Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stated, “We reached an important clinical development milestone in the first quarter of 2024.
  • Revenues: Revenues for the first quarters ended March 31, 2023 and 2024 were $41,883 and $1.1 million, respectively.
  • The Company incurred significant legal expenses in connection with this matter in the period ended March 31, 2024, and expects to continue to incur material costs and expenses through the third quarter of 2024.

Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Retrieved on: 
среда, мая 15, 2024
Insurance, Patient, CD4, Phenotype, Research and development, Clinical trial, AACR, Therapy, Safety, Cancer, Pancreatic cancer, Vaccination, ASCO, Immunization, G&A, CD8, Development, Memory, Pharmaceutical industry

BOSTON, May 15, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent corporate and clinical updates.

Key Points: 
  • BOSTON, May 15, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent corporate and clinical updates.
  • R&D expense for the first quarter of 2024 was $7.6 million, compared to $5.5 million for the first quarter of 2023.
  • G&A expense for the first quarter of 2024 was $2.7 million, compared to $2.3 million for the first quarter of 2023.
  • Net loss per share for the first quarter of 2024 was $1.15 compared to $24.77 for the first quarter of 2023.